# Dextromethorphan qualification report

esqLABS GmbH

## 2023-09-21 18:04:06

## Table of Content

1	Notes	2
2	Introduction	3
3	Methods   3.1 Software   3.2 Qualification process   3.3 Data   3.4 Model consolidation	<b>3</b> 3 3 3 3
4	Results	3
5	Conclusion	18

## 1 Notes

i Note

This report has been created with simulation results loaded from results folder .

### 2 Introduction

This document describes the qualification of a published Dextromethorphan physiologicallybased pharmacokinetics (PBPK) model for use with the Open Systems Pharmacology Software (OSPS) Version 11.2.

The PBPK model has been developed with OSPS version 10 and published by [@rudesheim-PhysiologicallyBasedPharmacokinetic2022]. Model snapshot was downloaded on 21.07.2023 from the model repository. As of 21.07.2023, no model version qualified for OSP version 11.2 is publicly available.

### 3 Methods

#### 3.1 Software

The qualification is performed with OSPS version 11.2.142.

#### 3.2 Qualification process

- 1. Import project snapshot "Dextromethorphan-model.json" in PK-Sim v11.2.
- 2. The snapshot contains 33 simulations. All simulations were exported to \*.pkml for simulation in R.
- 3. All observed data from the project created with version 11.2 were exported \*.pkml for loading in R.
- 4. Simulations were simulated in R and the results visually compared to the results reported in the original publication.

#### 3.3 Data

#### 3.4 Model consolidation

During conversion of projects created with versions before 11, a separate expression profile is created for each individual. To ensure that all individuals are using the same expression, expression profiles of the same protein were compared. All expression profiles for the same protein were equal. Therefore, the same expression profile was set in every individual, and the remaining profiles were removed.

### 4 Results

Comparison of time-concentration profiles with observed data are presented in the following:

## Antecip Bioventures EM, 60 mg dextromethorphan hydrobromide multiple dose (capsule/solution), n=10 - time profile



Figure 1: Antecip Bioventures EM, 60 mg dextromethorphan hydrobromide multiple dose (capsule\_solution), n=10



Armani 2017 EM, 30 mg dextromethorphan hydrobromide (cocktail), n=20 - time profile

Figure 2: Armani 2017 EM, 30 mg dextromethorphan hydrobromide (cocktail), n=20

Capon 1996 EM, 30 mg dextromethorphan hydrobromide (capsule/solution), n=6 - time profile



Figure 3: Capon 1996 EM, 30 mg dextromethorphan hydrobromide (capsule\_solution), n=6



Capon 1996 PM, 30 mg dextromethorphan hydrobromide (capsule/solution), n=6 - time profile

Figure 4: Capon 1996 PM, 30 mg dextromethorphan hydrobromide (capsule\_solution), n=6



Duedahl 2005 EM, 0.5 mg/kg dextromethorphan base (infusion), n=24 - time profile

Figure 5: Duedahl 2005 EM, 0.5 mg\_kg dextromethorphan base (infusion), n=24











Figure 7: Edwards 2017 EM, 30 mg dextromethorphan hydrobromide (capsule\_solution), n=48









Feld 2013 EM, 60 mg dextromethorphan hydrobromide (capsule/solution), n=17 - time profile

Figure 9: Feld 2013 EM, 60 mg dextromethorphan hydrobromide (capsule\_solution), n=17











Figure 11: Gorski 2004 EM, 30 mg dextromethorphan hydromide (capsule\_solution), n=11



Gorski 2004 PM, 30 mg dextromethorphan hydromide (capsule/solution), n=1 - time profile







Figure 13: Kakuda 2014 EM, 30 mg dextromethorphan hydrobromide (cocktail), n=14



Khalilieh 2018 EM, 30 mg dextromethorphan hydrobromide (cocktail), n=20 - time profile



## Nakashima 2007 EM, 30 mg dextromethorphan hydrobromide (capsule/solution), n=24 - time profile



Figure 15: Nakashima 2007 EM, 30 mg dextromethorphan hydrobromide (capsule\_solution), n=24



Nyunt 2008 EM, 30 mg dextromethorphan hydrobromide (cocktail), n=12 - time profile

Figure 16: Nyunt 2008 EM, 30 mg dextromethorphan hydrobromide (cocktail), n=12

Qiu 2016 IM, 15 mg dextromethorphan hydrobromide (capsule/solution), n=6, AS=0.5 - time profile



Figure 17: Qiu 2016 IM, 15 mg dextromethorphan hydrobromide (capsule\_solution), n=6, AS=0.5





Figure 18: Qiu 2016 NM, 15 mg dextromethorphan hydrobromide (capsule\_solution), n=6, AS=1.25

Qiu 2016 NM, 15 mg dextromethorphan hydrobromide (capsule/solution), n=6, AS=2 - time profile



Figure 19: Qiu 2016 NM, 15 mg dextromethorphan hydrobromide (capsule\_solution), n=6, AS=2



Sager 2014 EM, 30 mg dextromethorphan hydrobromide (cocktail), n=10 - time profile







Figure 21: Schadel 1995 EM, 30 mg dextromethorphan hydrobromide (capsule\_solution), n=5



Schadel 1995 PM, 30 mg dextromethorphan hydrobromide (capsule/solution), n=4 - time profile







Figure 23: Stage 2018 EM, 30 mg dextromethorphan hydrobromide (cocktail), n=12









Storelli 2018 NM, 5 mg dextromethorphan base (capsule/solution), n=17, AS=2 - time profile









## Yamazaki 2017 IM, 30 mg dextromethorphan hydrobromide (capsule/solution), n=12, AS=0.5 - time profile



Figure 27: Yamazaki 2017 IM, 30 mg dextromethorphan hydrobromide (capsule\_solution), n=12, AS=0.5

# Yamazaki 2017 NM, 30 mg dextromethorphan hydrobromide (capsule/solution), n=11, AS=2 - time profile



Figure 28: Yamazaki 2017 NM, 30 mg dextromethorphan hydrobromide (capsule\_solution), n=11, AS=2

## Zawertailo 2009 NM, 3 mg/kg dextromethorphan hydrobromide (capsule/solution), n=6, AS=2 - time profile



Figure 29: Zawertailo 2009 NM, 3 mg\_kg dextromethorphan hydrobromide (capsule\_solution), n=6, AS=2

### **5** Conclusion

All simulations that are available in the snapshot produced the same results as in the original publication (by visual comparison). Not all reported simulations are implemented in the snapshot, their comparison was not possible. It is, however, assumed that the model behaves exactly as described in the original publication.